Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path

With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal